Latent Infection: Clinical Trials

22 trials for Latent Infection, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

9 completed, 4 recruiting, 4 unknown, 2 terminated. 22 Phase 3, 6 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 322Completed 9, Recruiting 4, Unknown 4, Terminated 2, Active not recruiting 1, Suspended 1, Withdrawn 1
Phase 26Recruiting 3, Unknown 2, Active not recruiting 1

Follow Latent Infection: new trials by email Literature Review of Latent Infection trials Research Report on Latent Infection

Trials (filtered) newest first · largest first

All 22 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Bedaquiline Roll-out Evidence in Contacts and People Living With HIV to Prevent TB
Bedaquiline, Isoniazid, rifapentine, Levofloxacin - Tuberculosis, Latent
Phase 2 / Phase 3RecruitingJohns Hopkins University25302026-05-082026-10-20
Shorter and Safer Treatment Regimens for Latent TB
rifampin standard arm, rifampin double dose, levofloxacin and rifapentine - Tuberculosis Infection, Latent
Phase 2 / Phase 3RecruitingMcGill University Health Centre/Research Institute of the McGill University Health Centre18002025-06-102026-05-11
1HP Versus 3HR in the Treatment of Tuberculosis Infection in Vietnam
Isoniazid, Rifapentine, Rifampicin - Tuberculosis Infection
Phase 3WithdrawnFreundeskreis Für Internationale Tuberkulosehilfe e.V2024-11-012026-09-09
BCG Revaccination in Children and Adolescents
BCG vaccine, Oral Chemoprophylaxis - Tuberculosis Infection, Tuberculosis
Phase 3SuspendedTuberculosis Research Centre, India92002024-07-152023-12-18
Short-course Regimens for the Treatment of Pulmonary Tuberculosis
Rifabutin, Delamanid, Bedaquiline - Tuberculosis, Pulmonary, Tuberculosis Infection
Phase 2 / Phase 3Active not recruitingCenters for Disease Control and Prevention2882023-11-212026-09-21
A Novel Therapy With a 1-Month Ultrashort Regimen to Halt Progression From Latent Infection to Active Tuberculosis Among Close Contacts (The TB-YOUTH Study)
isoniazid and rifapentine, Rifampin and Isoniazid - Tuberculosis, Latent Tuberculosis
Phase 3RecruitingHuashan Hospital35202023-09-012026-07-14
Clinical Study of Recombinant Mycobacterium Tuberculosis Fusion Protein for 65-year-olds and Above
Recombinant Mycobacterium Tuberculosis Fusion Protein, Purified Protein Derivative of Tuberculin - Latent Tuberculosis Infection
Phase 3CompletedAnhui Zhifei Longcom Biologic Pharmacy Co., Ltd.7802023-08-032026-04-30
Immunization With BCG Vaccine to Prevent Tuberculosis Infection
BCG (Tokyo 172) vaccine, Placebo - Tuberculosis Infection
Phase 3TerminatedHenry M. Jackson Foundation for the Advancement of Military Medicine162021-12-012026-01-23
Alternative Antibiotics for Syphilis
Linezolid 600 mg (post-interim), Benzathine Penicilllin G (post-interim) - Early Latent Syphilis, Primary Syphilis
Phase 3CompletedFundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia1652021-10-142026-07-29
Cyclophosphamide in the Treatment of Refractory Proliferative Arachnoiditis in CNS Tuberculosis
Cyclophosphamide injection - Tuberculosis, Tubercular Meningitis
Phase 2 / Phase 3UnknownAll India Institute of Medical Sciences402021-01-012020-12-30
Risk of SDRs Under 3HP and 1HP Regimen for LTBI
isoniazid and rifapentine - Latent Tuberculosis Infection
Phase 3CompletedNational Taiwan University Hospital4902019-09-242023-12-26
Assessment of the Safety, Tolerability, and Effectiveness of Rifapentine Given Daily for LTBI
Rifapentine daily for 6 weeks, Rifapentine and Isoniazid weekly for 12 weeks, Rifampin and Isoniazid daily for 12 weeks - Latent Tuberculosis
Phase 2 / Phase 3RecruitingCenters for Disease Control and Prevention34002019-08-012026-05-06
Trial of Vitamin D Supplementation in Cape Town Primary Schoolchildren
Cholecalciferol, Placebo - Latent Tuberculosis
Phase 3CompletedQueen Mary University of London17432017-03-142022-09-08
Efficacy of Nyaditum Resae(R) Against Active TB in Georgia
Nyaditum resae(R), Placebo - Close Contacts of Active Tuberculosis
Phase 2 / Phase 3UnknownFundació Institut Germans Trias i Pujol33002017-03-102017-09-07
Vitamin D Supplementation in TB Prevention
Cholecalciferol (vitamin D3), Placebo - Latent Tuberculosis
Phase 3CompletedHarvard School of Public Health (HSPH)88512015-09-012020-07-16
Toward a Safe and Reachable Preventive Therapy for LTBI: a Multicenter Randomized Controlled Study in Taiwan
Rifapentine and Isoniazid for 3 months, Isoniazid for 9 months - Latent Tuberculosis Infection
Phase 3UnknownNational Taiwan University Hospital2832014-08-012016-12-15
Study 33: Adherence to Latent Tuberculosis Infection Treatment 3HP SAT Versus 3HP DOT
Self Administered Therapy (SAT), SMS reminders, isoniazid and rifapentine - Latent Tuberculosis Infection
Phase 3CompletedCenters for Disease Control and Prevention10022012-09-012025-03-13
"Efficacy and Safety of Levofloxacin vs Isoniazid in Latent Tuberculosis Infection in Liver Transplant Patients".
Levofloxacin, Isoniazid - Latent Tuberculosis Infection, Infection in Solid Organ Transplant Recipients
Phase 3TerminatedFundación Pública Andaluza para la gestión de la Investigación en Sevilla682012-01-012014-08-06
Rifampin Versus Isoniazid for the Treatment of Latent Tuberculosis Infection in Children (P4v9)
Isoniazid, Rifampin - Latent Tuberculosis Infection
Phase 3CompletedMcGill University8442011-08-012017-12-19
Comparing Two Preventive Regimens for Latent Tuberculosis Infection (LTBI)
4-month rifampin vs. 9-month isoniazid - Latent Tuberculosis Infection
Phase 3UnknownNational Taiwan University Hospital3002011-05-012011-07-20

Showing 20 of 22. Sign in to see all of them.

Narrower conditions

Latent Tuberculosis (21)  ·  Tuberculosis (9)  ·  Arachnoiditis (1)  ·  Mycobacterium Infections (1)  ·  Syphilis (1)  ·  Syphilis, Latent (1)  ·  Syphilis, primary (1)  ·  Syphilis, secondary (1)  ·  Treponemal Infections (1)  ·  Tuberculosis, Meningeal (1)  ·  Tuberculosis, Pulmonary (1)

Broader conditions

Bacterial Infections (22)  ·  Bacterial Infections and Mycoses (22)  ·  Infections (22)  ·  Actinomycetales Infections (21)  ·  Gram-Positive Bacterial Infections (21)  ·  Mycobacterium Infections (20)  ·  Tuberculosis (12)  ·  Central Nervous System Bacterial Infections (1)  ·  Central Nervous System Diseases (1)  ·  Central Nervous System Infections (1)  ·  Communicable Diseases (1)  ·  Genital Diseases (1)  ·  Gram-Negative Bacterial Infections (1)  ·  Lung Diseases (1)

Interventions

Isoniazid (11)  ·  rifapentine (8)  ·  Rifampin (6)  ·  Levofloxacin (3)  ·  Cholecalciferol (2)  ·  Moxifloxacin (2)  ·  bedaquiline (2)  ·  BCG Vaccine (1)  ·  Chemoprevention (1)  ·  Clarithromycin (1)  ·  Cyclophosphamide (1)  ·  Ethambutol (1)  ·  Linezolid (1)  ·  OPC-67683 (1)  ·  Pyrazinamide (1)

Sponsors

Centers for Disease Control and Prevention (3)  ·  National Taiwan University Hospital (3)  ·  McGill University (2)  ·  All India Institute of Medical Sciences (1)  ·  Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. (1)  ·  Centre Hospitalier Universitaire, Amiens (1)  ·  Freundeskreis Für Internationale Tuberkulosehilfe e.V (1)  ·  Fundació Institut Germans Trias i Pujol (1)  ·  Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia (1)  ·  Fundación Pública Andaluza para la gestión de la Investigación en Sevilla (1)  ·  Harvard School of Public Health (HSPH) (1)  ·  Henry M. Jackson Foundation for the Advancement of Military Medicine (1)  ·  Huashan Hospital (1)  ·  Johns Hopkins University (1)  ·  McGill University Health Centre/Research Institute of the McGill University Health Centre (1)

Countries

Canada (5)  ·  Benin (4)  ·  South Africa (4)  ·  United States (4)  ·  Vietnam (4)  ·  Australia (3)  ·  Brazil (3)  ·  China (3)  ·  Indonesia (3)  ·  Spain (3)  ·  Taiwan (3)  ·  Uganda (3)  ·  Ghana (2)  ·  Guinea (2)  ·  Haiti (2)

Top investigators

Dick Menzies, MD (3)  ·  Robert Belknap, MD (2)  ·  Aishwarya Venkataraman, MRCPCH (1)  ·  Amber Robinson, PhD (1)  ·  Andrey S Borisov, MD, MPH (1)  ·  Daniel W Fitzgerald, MD (1)  ·  Davaasambuu Ganmaa, MD PhD (1)  ·  Dick Menzies, MD, MSc (1)  ·  Ekaterina V Kurbatova, MD, PhD, MPH (1)  ·  Eric Nuermberger, MD (1)  ·  Jann-Yuan Wang, MD, PhD (1)

Results publications

PMID 31866327, PMID 32539440, PMID 32785709, PMID 36949623, PMID 20627913, PMID 25404412, PMID 28043488, PMID 29114781, PMID 29393655, PMID 30029896, PMID 30067928, PMID 30067931, PMID 32706534, PMID 36441522, PMID 36730240, PMID 36815322, PMID 38048799, PMID 38211601, PMID 38599800, PMID 38996972, PMID 39345833, PMID 40326358, PMID 40915316, PMID 42247627